These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 26272227

  • 1. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV, Ustyugova A, Urbich M, Lamotte M, Sunderland T.
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [Abstract] [Full Text] [Related]

  • 2. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV, Hösel V, Ustyugova A, De Francesco M, Lamotte M, Sunderland T.
    J Med Econ; 2016 Oct; 19(1):1-10. PubMed ID: 26390231
    [Abstract] [Full Text] [Related]

  • 3. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Ageno W, Casella IB, Han CK, Raskob GE, Schellong S, Schulman S, Singer DE, Kimura K, Tang W, Desch M, Goldhaber SZ.
    Thromb Haemost; 2017 Jan 26; 117(2):415-421. PubMed ID: 27853808
    [Abstract] [Full Text] [Related]

  • 4. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M.
    J Med Econ; 2015 Jun 26; 18(6):399-409. PubMed ID: 25586203
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism.
    Monahan M, Ensor J, Moore D, Fitzmaurice D, Jowett S.
    J Thromb Haemost; 2017 Aug 26; 15(8):1591-1600. PubMed ID: 28520199
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
    Goldhaber SZ, Eriksson H, Kakkar A, Schellong S, Feuring M, Fraessdorf M, Kreuzer J, Schueler E, Schulman S.
    Vasc Med; 2016 Dec 26; 21(6):506-514. PubMed ID: 27807306
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT.
    Clin Ther; 2016 Mar 26; 38(3):478-93.e1-16. PubMed ID: 26922297
    [Abstract] [Full Text] [Related]

  • 8. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E.
    Vasc Health Risk Manag; 2014 Mar 26; 10():627-39. PubMed ID: 25404858
    [Abstract] [Full Text] [Related]

  • 9. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L.
    J Manag Care Pharm; 2005 Oct 26; 11(8):663-73. PubMed ID: 16194130
    [Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
    van Leent MW, Stevanović J, Jansman FG, Beinema MJ, Brouwers JR, Postma MJ.
    PLoS One; 2015 Oct 26; 10(8):e0135054. PubMed ID: 26241880
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM, Silva MA, Donovan JL, Kanaan AO.
    Clin Ther; 2014 Oct 01; 36(10):1454-64.e3. PubMed ID: 25092394
    [Abstract] [Full Text] [Related]

  • 12. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G, Stumpo C, Smith R, Bartle W.
    Am J Cardiovasc Drugs; 2009 Oct 01; 9(1):45-58. PubMed ID: 19178131
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI, Bunz TJ, Turpie AGG.
    Thromb Haemost; 2017 Oct 05; 117(10):1841-1847. PubMed ID: 28640322
    [Abstract] [Full Text] [Related]

  • 14. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P, Le HH, Raymond V, Mtibaa M, Moshyk A.
    J Med Econ; 2016 Jun 05; 19(6):557-67. PubMed ID: 26761644
    [Abstract] [Full Text] [Related]

  • 15. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ.
    Clin Ther; 2009 Jan 05; 31(1):194-212. PubMed ID: 19243718
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.
    Ann Intern Med; 2011 Jan 04; 154(1):1-11. PubMed ID: 21041570
    [Abstract] [Full Text] [Related]

  • 17. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
    Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, Hantel S, Feuring M, Kreuzer J.
    Thromb Haemost; 2015 Jul 04; 114(1):150-7. PubMed ID: 25739680
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J, Delaitre O, Hammès F, de Pouvourville G.
    Arch Cardiovasc Dis; 2014 Jul 04; 107(6-7):381-90. PubMed ID: 24973113
    [Abstract] [Full Text] [Related]

  • 19. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
    Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fernández C, Betegón-Nicolás L, de Salas-Cansado M, Rubio-Terrés C.
    Rev Esp Cir Ortop Traumatol; 2012 Jul 04; 56(6):459-70. PubMed ID: 23594943
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R, Kwong WJ, White RH, Goldhaber SZ.
    Hosp Pract (1995); 2015 Jul 04; 43(5):249-57. PubMed ID: 26549305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.